Clinical Trial Update: Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tipifarnib in HRAS-mutant head and neck squamous cell carcinoma has completed, with results posted assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: HRAS Gene Mutation, HNSCC | Phase 2 | Status: COMPLETED | Results posted: 2024-06-21